Literature DB >> 15769484

A novel anticoagulant purified from fish protein hydrolysate inhibits factor XIIa and platelet aggregation.

Niranjan Rajapakse1, Won-Kyo Jung, Eresha Mendis, Sung-Hoon Moon, Se-Kwon Kim.   

Abstract

A novel fish protein having anticoagulant and antiplatelet properties was enzymatically extracted from the marine fish, yellowfin sole (Limanda aspera) and purified to homogeneity producing an overall purification fold of 206.6. MALDI-TOF mass spectroscopic and SDS-PAGE analysis identified the purified protein as 12.01 kDa single-chain monomeric protein. It inhibited the activated coagulation factor XII (FXIIa) by forming an inactive complex regardless of Zn2+ mediation, and was named, yellowfin sole anticoagulant protein (YAP). In addition, YAP act to antagonize platelet membrane glycoprotein integrin, to arrest platelet aggregation. However, YAP was not able to block the adhesion of platelets to collagen, which mediate via major collagen receptors, GPIa/IIa on platelet membrane. Furthermore, YAP did not possess plasminogen activator-like activity to activate fibrinolysis. In fact, our findings indicate that YAP binds with FXIIa and platelet membrane integrins to inhibit thrombosis in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769484     DOI: 10.1016/j.lfs.2004.12.010

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  21 in total

Review 1.  Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases.

Authors:  Sinéad Lordan; R Paul Ross; Catherine Stanton
Journal:  Mar Drugs       Date:  2011-06-14       Impact factor: 6.085

Review 2.  Angiotensin-I-converting enzyme (ACE) inhibitors from marine resources: prospects in the pharmaceutical industry.

Authors:  Isuru Wijesekara; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

Review 3.  Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Roberto G S Berlinck; Mark T Hamann
Journal:  Biochim Biophys Acta       Date:  2009-03-19

Review 4.  Potential anti-HIV agents from marine resources: an overview.

Authors:  Thanh-Sang Vo; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-11-29       Impact factor: 5.118

5.  Synergistic activity of Fagonia arabica and Heteropneustes fossilis extracts against myocardial, cerebral infarction, and embolism disorder in mice.

Authors:  Rakesh Das; Atul Kaushik
Journal:  J Pharm Bioallied Sci       Date:  2010-04

Review 6.  Marine Peptides: Bioactivities and Applications.

Authors:  Randy Chi Fai Cheung; Tzi Bun Ng; Jack Ho Wong
Journal:  Mar Drugs       Date:  2015-06-29       Impact factor: 5.118

7.  Effects of organic extracts and their different fractions of five Bangladeshi plants on in vitro thrombolysis.

Authors:  Talha Bin Emran; Md Atiar Rahman; Mir Muhammad Nasir Uddin; Md Mominur Rahman; Md Zia Uddin; Raju Dash; Chadny Layzu
Journal:  BMC Complement Altern Med       Date:  2015-04-23       Impact factor: 3.659

8.  Membrane bioreactor technology for the development of functional materials from sea-food processing wastes and their potential health benefits.

Authors:  Se-Kwon Kim; Mahinda Senevirathne
Journal:  Membranes (Basel)       Date:  2011-10-25

9.  Effects of organic extracts of six Bangladeshi plants on in vitro thrombolysis and cytotoxicity.

Authors:  M Atiar Rahman; Rabeya Sultana; Talha Bin Emran; M Saiful Islam; M Ashiqur Rahman; Joti Sankhar Chakma; Harun-ur Rashid; Chowdhury Mohammad Monirul Hasan
Journal:  BMC Complement Altern Med       Date:  2013-01-30       Impact factor: 3.659

10.  Effect of Fagonia Arabica (Dhamasa) on in vitro thrombolysis.

Authors:  Sweta Prasad; Rajpal Singh Kashyap; Jayant Y Deopujari; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala
Journal:  BMC Complement Altern Med       Date:  2007-11-06       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.